Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same author

Deconvolving SARS-CoV-2 mRNA vaccine impact on immunotherapy-related survival.

Cancer discovery·2026
Same author

MYC pathway reprogramming through a TIP60 coactivator switch in neuroendocrine lineage transition in prostate cancer.

bioRxiv : the preprint server for biology·2026
Same author

Dependencies in heterogeneous, lineage plastic patient-derived prostate cancer organoids revealed through integrated single-cell multiomics and CRISPR screening.

bioRxiv : the preprint server for biology·2026
Same author

Single stereocenter inversion of a cyclic tetrapeptide enables the detoxification of lead-exposed mice.

Chemical science·2026
Same author

FOXA1 mutations co-opt nascent transcription factor networks in partnership with androgen receptor to enhance prostate tumorigenicity.

Cell reports·2026

Related Experiment Video

Updated: May 6, 2026

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling
10:07

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Published on: October 27, 2023

2.4K

Annotating MYC status with 89Zr-transferrin imaging.

Jason P Holland1, Michael J Evans, Samuel L Rice

  • 1Radiochemistry Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

Nature Medicine
|September 25, 2012
PubMed
Summary

A novel imaging agent, zirconium-89 labeled transferrin ((89)Zr-transferrin), can noninvasively detect early prostate cancer and monitor treatment response by measuring transferrin receptor 1 (TFRC) levels. This advance offers new possibilities for cancer diagnosis and targeted therapy.

More Related Videos

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.8K
Author Spotlight: Investigating mRNA Spatial Distribution in Drosophila Muscle Tissue
10:22

Author Spotlight: Investigating mRNA Spatial Distribution in Drosophila Muscle Tissue

Published on: September 8, 2023

2.2K

Related Experiment Videos

Last Updated: May 6, 2026

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling
10:07

Positron Emission Tomography Imaging of Cell Trafficking: A Method of Cell Radiolabeling

Published on: October 27, 2023

2.4K
Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts
09:21

Ferritinophagy: Assessing the Selective Degradation of Iron by Autophagy in Human Fibroblasts

Published on: February 23, 2024

1.8K
Author Spotlight: Investigating mRNA Spatial Distribution in Drosophila Muscle Tissue
10:22

Author Spotlight: Investigating mRNA Spatial Distribution in Drosophila Muscle Tissue

Published on: September 8, 2023

2.2K

Area of Science:

  • Oncology
  • Radiochemistry
  • Molecular Imaging

Background:

  • Targeted cancer therapies require noninvasive methods to measure oncogenic signaling pathway activity.
  • Transferrin receptor 1 (TFRC, CD71) is a key target in various cancers, often upregulated by oncogenes like MYC.

Purpose of the Study:

  • To develop and evaluate a novel positron emission tomography (PET) radiotracer for noninvasively quantifying TFRC expression.
  • To assess the utility of this tracer in detecting and monitoring MYC-driven prostate cancer.

Main Methods:

  • Development of zirconium-89 labeled desferrioxamine-transferrin ((89)Zr-transferrin) as a PET radiotracer.
  • In vivo imaging studies using MYC-driven prostate cancer xenograft and transgenic mouse models.
  • Quantitative analysis of (89)Zr-transferrin uptake correlating with TFRC expression and MYC activity.

Main Results:

  • (89)Zr-transferrin demonstrated high avidity binding to TFRC, producing high-contrast PET images.
  • PET imaging quantitatively reflected MYC-regulated TFRC changes in response to therapy in xenografts.
  • The tracer detected in situ prostate cancer development and prostatic intraepithelial neoplasia (PIN) prior to invasive cancer detection.

Conclusions:

  • (89)Zr-transferrin is a sensitive tool for noninvasive measurement of oncogene-driven TFRC expression.
  • This radiotracer shows promise for early prostate cancer detection and monitoring treatment efficacy.
  • Potential for application in other cancers with elevated TFRC and near-term clinical translation.